Boehringer's Nerandomilast Meets Primary Endpoint In Pivotal Phase-III FIBRONEERTM-IPF Study
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
The American Journal of Managed Care4d
FIBRONEER-IPF Trial of Nerandomilast Meets Primary End Point
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
pharmaphorum5d
Trial sets up filings for Boehringer IPF drug nerandomilast
Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...
clinicaladvisor.com5d
Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis Trial
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
BioSpace6d
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Outsourcing-pharma6d
Boehringer Ingelheim score with phase 3 idiopathic pulmonary fibrosis win
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Pharmabiz6d
Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint
Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...
Managed Healthcare Executive6d
IPF Drug Meets Primary End Point
Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.